Becker's Healthcare May 6, 2024
Erica Carbajal

In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal reported May 3.

This marks the agency’s second request for additional information regarding the deal, according to Catalent’s May 3 filing with the Securities and Exchange Commission. The move embodies the FTC’s heightened scrutiny on large mergers in recent years, especially in healthcare.

As part of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Govt Agencies, Mergers & Acquisitions / JV, Pharma / Biotech, Trends
Related Articles:
How AI is streamlining cell and gene therapy manufacturing
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Vertex challenger Sionna prices $191M IPO
Insights from JP Morgan 2025: Key trends shaping the pharma industry
Oral Metabolic Drug Acquired by Novo Nordisk Continues to Show Concerning Neuro Side Effects

Share This Article